These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 25188519)
1. Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Guo W; Liu R; Bhardwaj G; Yang JC; Changou C; Ma AH; Mazloom A; Chintapalli S; Xiao K; Xiao W; Kumaresan P; Sanchez E; Yeh CT; Evans CP; Patterson R; Lam KS; Kung HJ Cell Death Dis; 2014 Sep; 5(9):e1409. PubMed ID: 25188519 [TBL] [Abstract][Full Text] [Related]
2. CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors. Guo W; Liu R; Bhardwaj G; Ma AH; Changou C; Yang JC; Li Y; Feng C; Luo Y; Mazloom A; Sanchez E; Wang Y; Huang W; Patterson R; Evans CP; Lam KS; Kung HJ PLoS One; 2013; 8(8):e70910. PubMed ID: 23967135 [TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Dai B; Kim O; Xie Y; Guo Z; Xu K; Wang B; Kong X; Melamed J; Chen H; Bieberich CJ; Borowsky AD; Kung HJ; Wei G; Ostrowski MC; Brodie A; Qiu Y Cancer Res; 2006 Aug; 66(16):8058-64. PubMed ID: 16912182 [TBL] [Abstract][Full Text] [Related]
4. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Qiu Y; Robinson D; Pretlow TG; Kung HJ Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3644-9. PubMed ID: 9520419 [TBL] [Abstract][Full Text] [Related]
5. Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Dai B; Chen H; Guo S; Yang X; Linn DE; Sun F; Li W; Guo Z; Xu K; Kim O; Kong X; Melamed J; Qiu S; Chen H; Qiu Y Cancer Res; 2010 Jul; 70(13):5587-96. PubMed ID: 20570899 [TBL] [Abstract][Full Text] [Related]
6. Targeting Btk with ibrutinib inhibit gastric carcinoma cells growth. Wang JD; Chen XY; Ji KW; Tao F Am J Transl Res; 2016; 8(7):3003-12. PubMed ID: 27508020 [TBL] [Abstract][Full Text] [Related]
7. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378 [TBL] [Abstract][Full Text] [Related]
8. Dual phosphorylation of Btk by Akt/protein kinase b provides docking for 14-3-3ΞΆ, regulates shuttling, and attenuates both tonic and induced signaling in B cells. Mohammad DK; Nore BF; Hussain A; Gustafsson MO; Mohamed AJ; Smith CI Mol Cell Biol; 2013 Aug; 33(16):3214-26. PubMed ID: 23754751 [TBL] [Abstract][Full Text] [Related]
9. Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Tsai YT; Su YH; Fang SS; Huang TN; Qiu Y; Jou YS; Shih HM; Kung HJ; Chen RH Mol Cell Biol; 2000 Mar; 20(6):2043-54. PubMed ID: 10688651 [TBL] [Abstract][Full Text] [Related]
10. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Lee LF; Guan J; Qiu Y; Kung HJ Mol Cell Biol; 2001 Dec; 21(24):8385-97. PubMed ID: 11713275 [TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer. Kokabee L; Wang X; Sevinsky CJ; Wang WL; Cheu L; Chittur SV; Karimipoor M; Tenniswood M; Conklin DS Cancer Biol Ther; 2015; 16(11):1604-15. PubMed ID: 26383180 [TBL] [Abstract][Full Text] [Related]
12. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. Qi W; Cooke LS; Stejskal A; Riley C; Croce KD; Saldanha JW; Bearss D; Mahadevan D BMC Cancer; 2009 May; 9():142. PubMed ID: 19432987 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. Sakai I; Miyake H; Terakawa T; Fujisawa M Cancer Sci; 2011 Apr; 102(4):769-75. PubMed ID: 21214673 [TBL] [Abstract][Full Text] [Related]
14. Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin. Xue LY; Qiu Y; He J; Kung HJ; Oleinick NL Oncogene; 1999 Jun; 18(22):3391-8. PubMed ID: 10362360 [TBL] [Abstract][Full Text] [Related]
15. Protein-tyrosine phosphatase D1, a potential regulator and effector for Tec family kinases. Jui HY; Tseng RJ; Wen X; Fang HI; Huang LM; Chen KY; Kung HJ; Ann DK; Shih HM J Biol Chem; 2000 Dec; 275(52):41124-32. PubMed ID: 11013262 [TBL] [Abstract][Full Text] [Related]
16. Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia. Nomura T; Yamasaki M; Hirai K; Inoue T; Sato R; Matsuura K; Moriyama M; Sato F; Mimata H Mol Cancer; 2013 Apr; 12():27. PubMed ID: 23566222 [TBL] [Abstract][Full Text] [Related]
17. Functional roles of Src and Fgr in ovarian carcinoma. Kim HS; Han HD; Armaiz-Pena GN; Stone RL; Nam EJ; Lee JW; Shahzad MM; Nick AM; Lee SJ; Roh JW; Nishimura M; Mangala LS; Bottsford-Miller J; Gallick GE; Lopez-Berestein G; Sood AK Clin Cancer Res; 2011 Apr; 17(7):1713-21. PubMed ID: 21300758 [TBL] [Abstract][Full Text] [Related]
19. The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma. Zhuang J; Tu X; Cao K; Guo S; Mao X; Pan J; Huang B; Chen X; Gao Y; Qiu S J Exp Clin Cancer Res; 2014 Mar; 33(1):25. PubMed ID: 24606948 [TBL] [Abstract][Full Text] [Related]